N4 Pharma updates on patent filing

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its patent application for Nuvec®, filed in March 2020 (no. PCT/GB2021/050960 Gene Therapy Vectors).

The Company originally filed a Patent Cooperation Treaty (“PCT”) patent application for Nuvec® to be used to manufacture viral vectors and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments. Under the terms of the PCT application process and following feedback from an international patent search, the Company is now making enhancements to the claims of the applications in the territories in which it wishes to gain patent protection. N4 pharma is pursuing this patent application which, if granted, would be in addition to the patents it has exclusively licensed from the University of Queensland.

The Company has decided to focus its claims on the use of the specific spiky properties of Nuvec™ to load and transfect viral vectors, especially adenoviral vectors and lentiviral vectors. This is based on feedback from the examiner and further work the Company has done that has shown how combining Nuvec® with adenoviral vectors (in addition to its earlier work on lentiviral vectors) can lead to an improvement in vector performance and a reduction in the amount of the viral vector needed.

The Company has filed ongoing patent applications in the following territories: Europe (including UK); USA; Japan; India and Canada. It will also file applications in Australia and China in due course. 

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

“We are seeking to refine our claims to give this patent the greatest chance of being granted in a field with strong commercial opportunity. Should the patent be granted in these territories it would mirror the regions granted for the main patent which the Company has licensed from the University of Queensland and further strengthen the commercial protection of Nuvec®.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma updates on Nuvec AAV Viral Vector research

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, has provided a further successful update on its ongoing research work into the use of Nuvec® to

    N4 Pharma

    N4 Pharma plc Nuvec Oral Delivery Update

    N4 Pharma Plc (LON: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a positive update on its ongoing oral delivery research work. The Company through its research

    N4 Pharma

    N4 Pharma plc Nuvec® R&D and Strategy Update

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging update on its ongoing in vitro siRNA research work. The Company’s double loaded siRNA work is

    N4 Pharma

    N4 Pharma launch Interactive Investor Hub

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders,

    N4 Pharma

    N4 Pharma updated investor presentation

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition of a 71% interest in Nanogencis

    N4 Pharma

    N4 Pharma acquires of a controlling interest in Nanogenics

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, has announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited,

    N4 Pharma

    N4 Pharma granting of patent application in the United States

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced two operational updates. Granting of further US patent The University of Queensland has informed the Company that

    N4 Pharma

    N4 Pharma updates on in vitro results for Nuvec®

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its ongoing in vitro siRNA research work. BCL-2 assay has been established Further

    N4 Pharma

    N4 Pharma Nuvec well suited for working with siRNA

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing siRNA research work. The Company has completed the single loading

    N4 Pharma

    N4 Pharma well funded to deliver its siRNA programme

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December 2022. Highlights: • Nuvec® as a

    N4 Pharma

    N4 Pharma AGM to be held on 3 April 2023

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that its Annual Report and Accounts for the year ended 31 December 2022 and Notice

    N4 Pharma

    N4 Pharma Broker Offer to raise a maximum of £1 million

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did not participate in the fundraising announced

    N4 Pharma

    N4 Pharma raises £1million through a placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through a placing of 50,000,000 new ordinary